Alnylam Pharmace. buy StockNews.com
Summary
This prediction ended on 02:15 with a price of €141.55. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.81%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | 2.036% | 2.036% | -27.053% |
iShares Core DAX® | 0.476% | -0.039% | 13.342% |
iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% |
iShares Nikkei 225® | 1.300% | -2.135% | 19.861% |
iShares S&P 500 | 0.829% | 0.193% | 29.756% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.